Search

Marcela A Maus

from Lexington, MA
Age ~49
Get Report
Also known as:
Marcela V Maus, Marcela A Valderrama, Marcela Valderamma
Phone and address:
16 Richmond Cir, Lexington, MA 02421
Related to:
Douglas Maus
Connected to:
Anne B Maus, 81Bethany M Maus, 52Carol M Maus, 56Don Maus, 75Donna L Maus, 56Erin M Maus, 41Erin F Maus, 39Frederic A Maus, 84Gavin C Maus, 51George R Maus, 60

Marcela Maus Phones & Addresses

  • 16 Richmond Cir, Lexington, MA 02421
  • Marstons Mills, MA
  • Bryn Mawr, PA
  • New York, NY
  • 250 Wynnewood Ave, Wynnewood, PA 19096 (610) 896-9755
  • Sharon, CT
  • Brooklyn, NY
  • Cambridge, MA

Work

Company: Hospital of the University of Pennsylvania Address: 3400 Spruce Street, Philadelphia, PA 19104

Education

School / High School: Perelman School of Medicine University of Pennsylvania 2001

Languages

English

Specialities

Hematology • Hematology & Oncology

Professional Records

License Records

Marcela Valderrama Maus

Address:
Delaware
Bryn Mawr, PA 19010
License #:
MD446462 - Expired
Category:
Medicine
Type:
Medical Physician and Surgeon

Marcela Valderrama Maus

Address:
New York, NY 10065
License #:
MT188643 - Expired
Category:
Medicine
Type:
Graduate Medical Trainee

Medicine Doctors

Marcela Maus Photo 1

Dr. Marcela V Maus, Philadelphia PA - MD (Doctor of Medicine)

View page
Specialties:
Hematology
Hematology & Oncology
Address:
3400 Spruce St, Philadelphia, PA 19104
(215) 615-5858 (Phone)
Languages:
English
Hospitals:
3400 Spruce St, Philadelphia, PA 19104

Hospital of the University of Pennsylvania
3400 Spruce Street, Philadelphia, PA 19104
Education:
Medical School
Perelman School of Medicine University of Pennsylvania
Graduated: 2001
Marcela Maus Photo 2

Marcela Valderrama Maus

View page
Specialties:
Internal Medicine
Hematology & Oncology
Marcela Maus Photo 3

Marcela Valderrama Maus, Philadelphia PA

View page
Specialties:
Internist
Address:
3400 Spruce St, Philadelphia, PA 19104

Business Records

Name / Title
Company / Classification
Phones & Addresses
Marcela Valderrama Maus
Marcela Maus MD
Internist
3400 Spruce St, Philadelphia, PA 19104
(215) 662-2200

Publications

Us Patents

Activation And Expansion Of T-Cells Using An Agent That Provides A Primary Activation Signal And Another Agent That Provides A Co-Stimulatory Signal

View page
US Patent:
7670781, Mar 2, 2010
Filed:
Jan 3, 2003
Appl. No.:
10/336135
Inventors:
James Riley - Downingtown PA, US
Carl June - Merion Station PA, US
Marcela Maus - Wynnewood PA, US
International Classification:
G01N 33/567
G01N 33/53
C12N 15/00
C07K 16/00
US Classification:
435 71, 435 721, 435 724, 435440
Abstract:
The present invention relates to compositions and methods for activating and expanding T-cells. The T-cells are induced to proliferate by providing a primary activation signal and a co-stimulatory signal to the T cells.

Activation And Expansion Of T-Cells Using An Engineered Multivalent Signaling Platform As A Research Tool

View page
US Patent:
7745140, Jun 29, 2010
Filed:
Jun 13, 2003
Appl. No.:
10/461283
Inventors:
Carl June - Merion Station PA, US
James Riley - Downingtown PA, US
Marcela Maus - Wynnewood PA, US
Anna Thomas - Freiburg, DE
Robert Vonderheide - Merion Station PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
G01N 33/53
C12N 5/00
C12N 15/63
C07K 17/00
US Classification:
435 71, 435325, 435373, 435455
Abstract:
Provided are a system and methods for selectively inducing expansion of a population of T cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of CTLs, preferably human CTLs. In addition, T cell proliferation can be induced without the need for antigen, thus providing an expanded T cell population that is polyclonal with respect to antigen reactivity. Further provided are methods for using the system and methods to screen and identify antigens related to specific diseases or conditions, tumors, autoimmune disorders, or an infectious disease or pathogen, and to identify target molecule for research purposes, or for developing a vaccine based thereon.

Activation And Expansion Of T-Cells Using An Engineered Multivalent Signaling Platform As A Research Tool

View page
US Patent:
8637307, Jan 28, 2014
Filed:
May 10, 2010
Appl. No.:
12/777053
Inventors:
Carl H. June - Merion Station PA, US
James L. Riley - Downingtown PA, US
Marcela Maus - Wynnewood PA, US
Anna Thomas - Freiburg, DE
Robert Vonderheide - Merion Station PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
C12N 5/02
C12N 5/06
C12N 5/08
C12N 5/00
C07K 16/00
US Classification:
435325, 435326, 435355, 435372, 4353728
Abstract:
Provided are a system and methods for selectively inducing expansion of a population of T cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of CTLs, preferably human CTLs. In addition, T cell proliferation can be induced without the need for antigen, thus providing an expanded T cell population that is polyclonal with respect to antigen reactivity. Further provided are methods for using the system and methods to screen and identify antigens related to specific diseases or conditions, tumors, autoimmune disorders, or an infectious disease or pathogen, and to identify target molecule for research purposes, or for developing a vaccine based thereon.

Activation And Expansion Of T-Cells Using An Engineered Multivalent Signaling Platform

View page
US Patent:
20030224520, Dec 4, 2003
Filed:
Jan 3, 2003
Appl. No.:
10/336224
Inventors:
Carl June - Merion Station PA, US
James Riley - Downingtown PA, US
Marcela Maus - Wynnewood PA, US
Anna Thomas - Freiburg, DE
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
C12P021/02
C07H021/04
C07K014/705
C12N015/85
C12N005/08
US Classification:
435/455000, 435/069100, 435/372000, 530/350000, 536/023500
Abstract:
The present invention relates generally to methods for activating and expanding cells, and more particularly, to a novel method to activate and/or stimulate cells using an engineered multivalent signaling platform. Compositions of cells activated and expanded by the methods herein are further provided.

Activation And Expansion Of T-Cells Using An Engineered Multivalent Signaling Platform

View page
US Patent:
20040110290, Jun 10, 2004
Filed:
Jun 13, 2003
Appl. No.:
10/462207
Inventors:
Carl June - Merion Station PA, US
James Riley - Downingtown PA, US
Marcela Maus - Wynnewood PA, US
Anna Thomas - Freiburg, DE
Robert Vonderheide - Merion Station PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
C12N005/08
US Classification:
435/372000
Abstract:
The present invention relates generally to methods for activating and expanding cells, and more particularly, to a novel method to activate and/or stimulate cells using an engineered multivalent signaling platform. Compositions of cells activated and expanded by the methods herein are further provided.

Compositions And Methods For Detection And Modulation Of T Cell Mediated Immune Responses Against Viral Vectors Utilized For Gene Therapy

View page
US Patent:
20100035806, Feb 11, 2010
Filed:
May 31, 2007
Appl. No.:
12/302206
Inventors:
Katherine A. High - Merion PA, US
Marcela V. Maus - New York NY, US
Federico Mingozzi - Philadelphia PA, US
Daniel J. Hui - Chesterbrook PA, US
Assignee:
THE CHILDREN'S HOSPITAL OF PHILADELPHIA - PHILADELPHIA PA
International Classification:
A61K 48/00
C07K 14/715
C12Q 1/70
A61K 38/17
C12N 15/63
A61P 37/00
US Classification:
514 12, 530350, 435 5, 514 44 R, 4353201
Abstract:
Compositions and methods are provided for inhibiting T cell mediated destruction of virally transduced, trangene containing cells.

Engineered Immune Cells With Reduced Toxicity And Uses Thereof

View page
US Patent:
20230036569, Feb 2, 2023
Filed:
Dec 17, 2020
Appl. No.:
17/784935
Inventors:
- Boston MA, US
Marcela V. Maus - Lexington MA, US
Assignee:
The General Hospital Corporation - Boston MA
International Classification:
A61K 35/17
C07K 14/725
C12N 15/11
C12N 9/22
C12N 15/113
C07K 14/705
A61P 35/00
A61P 35/02
Abstract:
In the disclosure provided herein are engineered immune cells (e.g., T cells) deficient in INFy expression and have reduced toxicity. Methods of producing the engineered immune cells (e.g., T cells) and methods of using the engineered immune cells (e.g., T cells) to treat cancer or autoimmune disease are also provided.

Modified T Cells And Methods Of Their Use

View page
US Patent:
20210322473, Oct 21, 2021
Filed:
Jul 17, 2019
Appl. No.:
17/260613
Inventors:
- Boston MA, US
Marcela V. MAUS - Lexington MA, US
International Classification:
A61K 35/17
C12N 15/85
C12N 15/10
C07K 14/03
C07K 14/705
Abstract:
The technology described herein relates to modified T cells and their use in immunotherapeutic methods. In various examples, the T cells are modified so as to decrease or eliminate CD3ζ, TRAC, and/or TRBC expression.
Control profile
Marcela A Maus from Lexington, MA, age ~49 Get Report